Drug Profile
PF 2334
Alternative Names: PF-2334Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Neuroprotectants
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 16 Jul 2017 Preclinical trials in Alzheimer's disease in USA (unspecified route)
- 16 Jul 2017 Pharmacodynamics data from in vitro and preclinical studies in Alzheimer's disease presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)